LY2525623

LY2525623 is a humanized monoclonal antibody that targets interleukin-23 (IL-23), specifically the p19 subunit. Developed by Eli Lilly, it was investigated as an anti-inflammatory and antipsoriatic agent for autoimmune diseases such as plaque psoriasis. The drug acts by inhibiting IL-23-mediated signaling, which plays a central role in the expansion of Th17 cells and the pathogenesis of inflammatory diseases like psoriasis. By blocking IL-23, LY2525623 aims to reduce inflammation driven by T lymphocytes[1][2][3]. Development for plaque psoriasis reached Phase 2 clinical trials but was subsequently discontinued[2][3].

Other names

LY 2525623LY2525623LY-2525623